Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesCAI -0.89%11 EV-to-FCF is 32.38 as of Jul. 26, 2026, which is 4% above its 10-year median of 31.25. GuruFocus rates CAI with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 343 Biotechnology companies, Caris Life Sciences ranks worse than 70.55% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Caris Life Sciences's Enterprise Value is $3,997.5 Mil.
Caris Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $123.5 Mil. Therefore, Caris Life Sciences's EV-to-FCF for today is 32.38.
The historical rank and industry rank for Caris Life Sciences's EV-to-FCF or its related term are showing as below:
CAI'
s EV-to-FCF Range Over the Past 10 Years
Min: -650.91 Med: 31.25 Max: 114.87
Current: 32.38
During the past 4 years, the highest EV-to-FCF of Caris Life Sciences was 114.87. The lowest was -650.91. And the median was 31.25.
CAI's EV-to-FCF is ranked worse than 70.55% of 343
companies
in the Biotechnology industry
Industry Median: 14.7
vs CAI: 32.38
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Caris Life Sciences (NAS:CAI) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Caris Life Sciences's PE Ratio (TTM) for today is calculated as:
Caris Life Sciences's share price for today is $15.53.
Caris Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.610.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Caris Life Sciences EV-to-FCF Related Terms
Caris Life Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Caris Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caris Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's EV-to-FCF falls into.
Caris Life Sciences's current Enterprise Value is $3,997.5 Mil.
Caris Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $123.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caris Life Sciences (CAI) has a EV-to-FCF of 32.38 as of Jul. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Caris Life Sciences and its competitors. This is near median its historical median of 31.25. According to the industry distribution chart, Caris Life Sciences ranks #242 out of 343 companies in the Biotechnology industry, placing it in the top 70.6%.
Is Caris Life Sciences' EV-to-FCF too high?
Caris Life Sciences' current EV-to-FCF of 32.38 is near median its 10-year median of 31.25. The Biotechnology industry median EV-to-FCF is 14.70. Caris Life Sciences' value of 32.38 is 120.3% above this industry median. Based on the distribution chart, Caris Life Sciences ranks #242 out of 343 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Caris Life Sciences has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' EV-to-FCF compare to DNTH and MANE?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #242 out of 343 companies for EV-to-FCF. This places Caris Life Sciences in the lower half of its industry. The industry median EV-to-FCF is 14.70. Caris Life Sciences' value of 32.38 is 120.3% above this benchmark. While the company's 10-year median is 31.25 vs. the industry median of 14.70, Caris Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caris Life Sciences's current EV-to-FCF of 32.38 is 120.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Caris Life Sciences and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caris Life Sciences's current EV-to-FCF is 32.38, which is near median its own 10-year median of 31.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current EV-to-FCF of 32.38. The current EV-to-FCF is 32.38, which is near median its 10-year median of 31.25 and 120.3% above the Biotechnology industry median of 14.70. Caris Life Sciences' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current EV-to-FCF is 32.38 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
11GF Score
Get the complete analysis for CAI
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI has been successfully added to your 
